Paralytic peptide for use in neuromuscular therapy

Details Paralytic peptide for use in neuromuscular therapy Paralytic peptide for use in neuromuscular therapy

2003-11-18

2009-02-03

Weber, Jon P (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07485622

ABSTRACT:
The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the speciesBlarinaas a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic.

REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 6326020 (2001-12-01), Kohane et al.
patent: 10-236963 (1998-09-01), None
Cai, Z., et al. “Solution Structure of BmBkTx1, a New BKca1Channel Blocker from the Chinese ScorpionButhus martensi Karsch.”, Biochemistry, vol. 43, No. 13, pp. 3764-3771 (2004).
Christenbury, P. “A Study of the Ecology ofBlarina brevicaudain North Carolina and of the Effect of Shrew Toxin on the Liver and Kidneys of Mice.”; A thesis submitted to the Graduate Faculty of Wake Forest College in partial fulfillment of the requirements for the degree of Master of Arts in the Department of Biology; (Aug. 1966).
Dekker, E., et al. “The epithelial calcium channels, TRPV5 and TRPV6: from identification towards regulation.”, Cell Calcium 33, pp. 497-507 (2003).
Dufton, M. “Venomous Mammals”; Pharmac. Ther. vol. 53, pp. 199-215 (1992).
Ellis, S., et al., “Properties of a Toxin From the Salivary Gland of the XShrew,Blarina brevicauda”; The Journal of Pharmacology & Experimental Therapeutics; vol. 114, No. 2, pp. 127-137 (1955).
George, S., et al. “Blarina brevicauda”; Mammalian Species, No. 261, pp. 1-9, 3 figs (1986).
Kita, M., et al. “Blarina toxin, a mammalian lethal venom from the short-tailed shrewBlarina vrevicauda: Isolation and characterization.” PNAS, vol. 101, No. 20, pp. 7542-7547 (2004).
Lecchi, P., et al. “The Structure of Synenkephalin (Pro-Enkephalin1-73) Is Dictated by Three Disulfide Bridges”; Biochemical and Biophysical Research Communications, vol. 232, No. 3, pp. 800-805 (1997).
Martin, I. “Venom of the Short-Tailed Shrew (Blarina brevicauda) as an Insect Immobilizing Agent”, Journal of Mammalogy, vol. 62, No. 1, pp. 189-192 (1978).
Montell, C. “The Venerable Inveterate Invertebrate TRP Channels”; Cell Calcium 33, pp. 409-417 ((2003).
Mount Allison University “Potent Peptide Paralytic Agent”, Version 1 (Jun. 2003).
Mount Allison University “Potent Peptide Paralytic Agemt” Version 2 (Jul. 2003).
Peng, J-B, et al. “CaT1 Expression Correlates with Tumor Grade in Prostate Cancer”; Biochemical and Biophysical Research Communication, vol. 282, pp. 729-734 (2001).
Peng, J-B, et al. “Human Calcium Transport Protein CaT1”; Biochemical and Biophysical Research Communications, vol. 278, No. 2, pp. 326-332 (2000).
Phol, M., et al. “Molecular Cloning of the Helodermin and Exendin-4 cDNAs in the Lizard”; The Journal of Biol;ogical Chemistry, vol. 273, No. 16, pp. 9778-9784 (1998).
Pucek, M. “Chemistry and Pharmacology of Insectivore Venoms”; Chapter 3 of Venomous Animals and Their Venoms edited by W. Bucher, Academic Press, new York—London, pp. 43-50 (1968).
Smart, P. “Shrew Saliva Spells Relief? Prof. Jack Stewart makes breakthrough medial discovery”; The Argosy (Jan. 16, 2003).
“The venom of the shrew may be in the new Botox”; National Post, Science Section (Biochemistry) (Dec. 20, 2002).
Tomasi, T. “Function of Venom in the Short-Tailed ShrewBlarina brevicauda”; Journal of Mammalogy, vol. 59, No. 4, pp. 852-854 (1978).
Zhuang, L., et al. “Calcium-Selective Ion Channel, CaT1, Is Apically Localized in Gastrointestinal Tract Epithelia and is Aberrantly Expressed in Human Malignancies”; Laboratory Investigation, vol. 82, No. 12, pp. 1755-1764 (2002).
Pearson, O.P.; On The Cause and Nature of a Poisonous Action Produced by the Bite of a Shrew (Blarina Brevicauda); J. Mammalogy; (1942) 23; pp. 159-166.

Affiliated with

Also associated with

Rating

Paralytic peptide for use in neuromuscular therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Paralytic peptide for use in neuromuscular therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Paralytic peptide for use in neuromuscular therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4084172